ARC-10: A phase 3 study to evaluate zimberelimab plus domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non-small-cell lung cancer.

被引:0
|
作者
Chouaid, Christos
Ho, Gwo Fuang
Runglodvatana, Yotsawaj
He, Xian
Ahlers, Christoph Matthias
Pomponio, Debbie
Todd, Trever
Dang, Thao
Naidoo, Jarushka
机构
[1] Ctr Hosp Intercommunal Creteil, Creteil, France
[2] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia
[3] Vajira Hosp, Bangkok, Thailand
[4] Arcus Biosci Inc, Hayward, CA USA
[5] Gilead Sci Inc, Foster City, CA USA
[6] Beaumont Hosp, Dublin, Ireland
[7] RCSI Univ Hlth Sci, Dublin, Ireland
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
TPS9148
引用
收藏
页数:1
相关论文
共 50 条
  • [31] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    West, H
    Belt, RJ
    Wakelee, HA
    Bloss, LP
    Taylor, L
    Monberg, MJ
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 649S - 649S
  • [32] Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study
    Borghaei, H.
    Besse, B.
    Bardia, A.
    Mazieres, J.
    Popat, S.
    Augustine, B.
    D'Amelio, A., Jr.
    Barrios, D.
    Rugo, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S236 - S236
  • [33] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [34] KEYNOTE-042 5-YEAR SURVIVAL UPDATE: PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, PD-L1POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
    de Castro, Gilberto
    Kudaba, Iveta
    Wu, Yi-Long
    Lopes, Gilberto
    Kowalski, Dariusz M.
    Turna, Hande Z.
    Caglevic, Christian
    Zhang, Li
    Karaszewska, Boguslawa
    Laktionov, Konstantin K.
    Srimuninnimit, Vichien
    Bondarenko, Igor
    Kubota, Kaoru
    Mukherjee, Rinee
    Lin, Jianxin
    Souza, Fabricio
    Mok, Tony S. K.
    Cho, Byoung Chul
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A390 - A390
  • [35] Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial
    Georgoulias, Vassilis
    Androulakis, Nikolaos
    Kotsakis, Athanasios
    Hatzidaki, Dora
    Syrigos, Kostas
    Polyzos, Aris
    Agelidou, Athina
    Varthalitis, Loannis
    Ziras, Nikoalos
    Agelidou, Maria
    Chandrinos, Vassilis
    Boukovinas, Loannis
    Geroyianni, Alexandra
    Vamakas, Larnbros
    Mavroudis, Dirnitris
    LUNG CANCER, 2008, 59 (01) : 57 - 63
  • [36] Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1-high locally advanced non-small cell lung cancer.
    Lin, Steven H.
    Pugh, Stephanie L.
    Tsao, Anne S.
    Edelman, Martin Joseph
    Doemer, Anthony
    Simone, Charles B.
    Gandhi, Saumil
    Bikkina, Sai
    Karim, Nagla Fawzy Abdel
    Shen, Xinglei
    Badiyan, Shahed N.
    Higgins, Kristin Ann
    Chakravarti, Arnab
    Werner-Wasik, Maria
    Schellenkamp, John M.
    Paulus, Rebecca
    Bradley, Jeffrey D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer:: The Swedish Lung Cancer Study Group
    Sederholm, C
    Hillerdal, G
    Lamberg, K
    Kölbeck, K
    Dufmats, M
    Westberg, R
    Gawande, SR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) : 8380 - 8388
  • [38] PHASE I STUDY OF ORAL S-1 PLUS CISPLATIN WITH CONCURRENT RADIOTHERAPY FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER
    Kaira, Kyoichi
    Sunaga, Noriaki
    Yanagitani, Noriko
    Kawata, Tadayoshi
    Utsugi, Mitsuyoshi
    Shimizu, Kimihiro
    Ebara, Takeshi
    Kawamura, Hidemasa
    Nonaka, Tetsuo
    Ishikawa, Hitoshi
    Sakurai, Hideyuki
    Suga, Tatsuo
    Hara, Kenichiro
    Hisada, Takeshi
    Ishizuka, Tamotsu
    Nakano, Takashi
    Mori, Masatomo
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (01): : 109 - 114
  • [39] LATIFY: Phase 3 study of ceralasertib plus durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L) 1 and platinum-based therapy.
    Besse, Benjamin
    Castro, Gilberto
    Felip, Enriqueta
    Politi, Katerina A.
    Takahashi, Toshiaki
    Wang, Jie
    Dean, Emma
    Deans, Melissa
    Broadhurst, Helen
    Thiyagarajah, Piruntha
    Forde, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Leal, Ticiana A.
    Riess, Jonathan W.
    Jensen, Erin
    Zhao, Bin
    Pietanza, M. Catherine
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2339 - +